LYPD3 and non-small cell lung carcinoma: For the case of lupartumab-amadotin 39, the antibody is specific to the C4.4A antigen expressed in NSCLC and, as in the previous case, after internalization into cells, the toxin released is cys-amadotin 41, which exhibited a significantly better efficacy against NSCLC compared to cisplatin.